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ABSTRACT

A plasmid bearing a cDNA copy of the genome of bovine

viral diarrhea virus (BVDV), chimeric derivatives of the

plasmid and a method of producing an infectious bovine
Viral diarrhea virus using the plasmid are disclosed. The
invention relates to a plasmid DNA molecule that replicates
easily in E. coli and contains a Sufficient portion of the
genome of BVDV, cloned as cDNA, to be a suitable tem
plate to produce RNA in vitro which, upon transfection into
bovine cells, gives rise to infectious BVDV. The BVDV
created by the process of the invention can be engineered for
use as a Vector in many advantageous applications.
21 Claims, 10 Drawing Sheets
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It is a still further object of the invention to provide a
novel method for the analysis of virus replication.
It is a still further object of the invention to provide a
novel approach for vaccine development.
It is a still further object of the invention to provide a

PLASMID BEARING A CDNA COPY OF THE
GENOME OF BOVINE WRAL DIARRHEA

VIRUS, CHIMERIC DERIVATIVES
THEREOF, AND METHOD OF PRODUCING
AN INFECTIOUS BOVINE WRAL
DARRHEAVIRUS USING SAID PLASMID

BVDV infectious clone.

This application claims the benefit of U.S. Provisional
Application No. 60/018,246 filed May 24, 1996.

BRIEF DESCRIPTION OF THE DRAWINGS
1O

The above noted and other features of the invention will

RIGHTS IN THE UNITED STATES
GOVERNMENT

be better understood from the following detailed description,

This invention was made with federal support under NRI
grant 92-37204-7959 from the USDA. The United States
government has certain rights to the invention.

FIG. 1 is a block diagram illustrating the process of
forming BVDV clNA genomic clone;
FIG. 2 is a diagram of a portion of the process of FIG. 1;
FIG. 3 is a diagram of another portion of the process of

in which:
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BACKGROUND OF THE INVENTION

This invention relates to plasmids for viruses, methods for
engineering the plasmids and methods for analyzing virus
replication.
The bovine viral diarrhea virus, or BVDV, is the prototype
species in the Pestivirus genus of the Flaviviridae. Positive
strand RNA viruses, such as the poliovirus and the BVDV,
have a genome consisting of a Single molecule of RNA. Pure
RNA extracted from either highly concentrated and purified
poliovirus or BVDV can be transfected into a susceptible
cell, which results in the production of infectious progeny
virus by the cell. A homogeneous preparation of viral RNA
molecules is infectious upon transfection.

FIG. 1;

FIG. 4 is a diagram of another portion of the process of
FIG. 1;

FIG. 5 is a diagram of another portion of the process of
FIG. 1;

FIG. 6 is a diagram of another portion of the process of
FIG. 1;
25

nucleotide 2040 and 3600 from 3 different viruses: the two

parental and the chimeric derivative.

The usefulness of RNA molecules from BVDV and

poliovirus is limited because they are many thousand nucle
otides in length and cannot be engineered in vitro to change
their Sequence using current technology. By contrast, DNA
molecules of Similar length, cloned into plasmids, can be
manipulated with restriction enzymes and Synthetic oligode
Oxynucleotides to obtain any desired Sequence.
It is known that the entire RNA sequence of some viruses
can be cloned into a plasmid. Such plasmids can be used to
produce RNA molecules in vitro that mimic the properties of
the RNA extracted from the purified virus. The RNA syn
thesized in Vitro using a plasmid DNA as a template pro
duces the virus upon transfection into Susceptible cells.
Plasmids with this property are known as “infectious
clones.”

BVDV remains enzootic in cattle populations throughout
the World. Current vaccines are either relatively unsafe or
ineffective in control and eradication programs. Efficient
reverse genetics approaches using an infectious molecular
clone of the BVDV genome may contribute to the develop
ment of rationally-designed Safe and efficacious vaccines.

DETAILED DESCRIPTION OF THE
INVENTION
35

40

(1) the development of attenuated or avirulent virus
(2) the addition of foreign Sequences encoding proteins of
45

immunological interest, Such as proteins from other para
Sites or viruses, Such as foot and mouth disease, leading to
the use of BVDV as a vector to vaccinate against other
infectious or parasitic diseases,

50

C3d complement molecule interleukins and the like;

(3) the addition of immunostimulatory molecules, Such as
(4) the development of marker vaccines with a charac
teristic deletion which allows the discrimination between

vaccinated and infected animals by retrospective Serological
55

tests,

(5) the development of sequence-tagged BVDV vaccines
which allow identification of the origin of the BVDV in the
event of alleged vaccine-associated outbreaks,

after.

(6) the mapping of attenuating mutations leading to

SUMMARY OF THE INVENTION

Accordingly, it is an object of the invention to provide a
novel plasmid.
It is a further object of the invention to provide a novel
method for engineering a plasmid.
It is a further object of the invention to provide a novel
method for engineering the genome of BVDV for vaccine
development.

The present invention relates to a plasmid DNA molecule
that replicates easily in Escherichia coli bacteria and con
tains a sufficient portion of the genome of BVDV, cloned as
cDNA, to be a suitable template to produce RNA in vitro,
which upon transfection into bovine cells, gives rise to
infectious BVDV. The BVDV created by this process can be
engineered as a vector for use in the following applications:
Strains for use as live vaccines,

The construction of an infectious molecular clone of

BVDV, its Subsequent modification to introduce a sequence
tagged site and the production of a chimeric virus expressing
a Surface glycoprotein from a different Strain, manipulating
the BVDV genome in vitro and its potential effectiveness for
reverse genetic analyses of pestivirus are described herein

FIG. 7 is a table describing starting plasmids for the
production of the chimeric virus of this invention; and
FIG. 8 is a diagram illustrating the nucleotide Sequence
alignment of the region of the BVDV genome between

60

avirulent phenotypes, and

(7) the identification of novel antiviral targets against
pestivirus and related flaviviruses by creation of suitable
chimeric viruses.
65

Five plasmids from the work of Collett et al., “Molecular
Cloning and Nucleotide Sequence of the Pestivirus Bovine
Viral Diarrhea Virus,” Virology 165, 191-199, were used as
a Starting material for the present invention. Cultures of

6,001,613
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the tailoring of Signals of RNA transcription, and the engi
neering of cleavage Sites for linearization of the DNA prior
to transcription. A Single nucleotide deletion present in the

3
these plasmids are maintained in Several private cultures,
Veterinary Basic Science Building, Department of Veteri
nary Science, University of Nebraska, Lincoln, Nebr. 68583,

one of which is in the refrigerator (Room VBS 151) in the

glycoprotein-encoding region of the virus (nt 2702) is

designated: (1) pBV-18; (2) pBV-116b; (3) pBV-D79; (4)
pBV-F2; and (5) pBVSD2-3". These cultures will be made
available upon granting of the patent. These plasmids are

described in FIG. 7.

From these plasmids, six vectors have been constructed:

(1) a plasmid containing a chimeric genome of BVDV, Strain

NADL, with Singer Strain E2/gp53 glycoprotein, propagated
in E. coli strain GM119, culture designated as pVVNADL
Singp, maintained in a private repository at the campus of

the University of Nebraska, in a refrigerator (Room VBS
151), in the Veterinary Basic Science Building, Department
of Veterinary Science, Lincoln, Nebr. 68503 (ATCC No
97572); (2) a plasmid containing sequence-tagged genome

15

of BVDV, strain NADL, in E. coli strain GM110, in a culture

antibodies (Mabs) to the viral glycoproteins. The integrity of

designated as pVVNADL delta Dra maintained in a private
repository at the campus of the University of Nebraska, in a

the ORF was confirmed and it was determined that the 3'

refrigerator (Room VBS 151), in the Veterinary Basic Sci

ence Building, Department of Veterinary Science, Lincoln,

Nebr. 68503 (ATCC No. 97573); (3) a plasmid pVVNADL
in a culture designated as pVVNADL maintained in a
private repository at the campus of the University of

Nebraska, in a refrigerator (Room VBS 151), in the Veteri

25

nary Basic Science Building, Department of Veterinary

Science, Lincoln, Nebr. 68503; (4) a Chimeric BVDV.

i-VVNADL-Singp, in a culture designated as i-VVNADL
maintained in a private repository at the campus of the

University of Nebraska, in a refrigerator (Room VBS 151),

in the Veterinary Basic Science Building, Department of
35

refrigerator (Room VBS 151), in the Veterinary Basic Sci

ence Building, Department of Veterinary Science, Lincoln,

Nebr. 68503; and (6) a virus i-VVNADL in a culture

designated as i-VVNADL maintained in a private repository
at the campus of the University of Nebraska, in a refrigerator

40

(Room VB5 151), in the Veterinary Basic Science Building,

Department of Veterinary Science, Lincoln, Nebr. 68583.
Missing Sequences were incorporated at four locations
and the plasmids were joined to construct a single plasmid
with the entire BVDV genome as cDNA: pVVNADL. An E.

45

plasmid (pVVNADL) is not stable in some other E. coli

50

hosts, such as MC1061, JM105, JM109, Sure, DH.5a. The

precise molecular basis of the increased stability in GM119
is unknown. The BVDV genome can be custom-tailored in
the infectious clone plasmid pVVNADL, or one of its
precursors: pBV18-F2 and p50Meu-3". Two examples are as

55

(a) BVDV with a unique sequence tag, i-VVNADL delta
60

(b) a chimeric BVDV virus, i-VVNADL Singp, which
replicates like a wild-type (WT) virus in spite of the
chimeric nature of its genome and its antigenic differ
ences detected with monocolonal antibodies.

As part of this process, the 5' and 3' termini of the BVDV
genome were reconstructed. This reconstruction includes the
addition of BVDV genomic Sequences missing or corrupted,

presence of the cap analog had less infectivity than
uncapped RNA. RNA Synthesis with cap analog and reduced
concentration of GTP very likely results in truncated tran
scripts. The phenotype of the virus rescued from pVVNADL
transcripts, termed i-VVNADL, was studied in vitro.
Infectious BVDV was produced by cells transfected with
uncapped RNA transcribed in vitro. The DNA template for
RNA production consisted of a plasmid containing the entire
genome of BVDV, cloned as cDNA. The internal ribosome

entry site element in the 5'-untanslated region (UTR) of the

follows:

Dra, was created which is neutral with respect to
phenotypic properties of BVDV; and

genome With an exact 3' end was ascertained by gel elec
trophoresis and Northern Blotting. RNA synthesized in vitro
was used to transfect EBTr cells by electroporation.
Controls included the electroporation of a transcription
mix lacking template DNA or T7 DNA polymerase. Fol
lowing electroporation, cells were distributed into dishes
containing glass coverslips to allow fixation and immunof
luorescence Staining. Cells were monitored for possible
Signs of cytopathology. Monolayers on glass coverSlips were
fixed at 24 and 48 hours after electroporation and Stained
with Mab to the p80/N53 protein. Supernatant fluid from
these wells was collected to check the phenotype of the
rescued virus. RNA transcripts made in vitro were

infectious, yielding ~10 TCIDso/ug. RNA transcribed in the

coli, strain GM119, (genotype: F-SupE44 lacY1 galK2
galT22 metB1 dam-3 dcm-6 tSX-78 lambda-) was used in the

preferred embodiment because of the increased plasmid
stability provided by this E. coli strain. The infectious clone

UTR of the virus is not required for translation. After this,
a full-length cDNA clone, termed pVVNADL was obtained
by joining a fragment of DNA derived from p3V18-F2 to
plasmid P5DMeu-3'.
RNA transcripts from the full-length BVDV genome
clones in pVVNADL were generated using the following
procedure: DNA was linearized with SacII restriction
endonuclease, which cleaves pVVNADL at the 3'-end of the
BVDV genome. This DNA was used as template for in vitro
transcription with T7 RNA polymerase with or without
removing the 3'-overhand left by SacII. Transcription with
the cap analog and transfection of the capped RNA were also
tested. Production of RNA molecules identical to the BVDV

Veterinary Science, Lincoln, Nebr. 68503 (ATCC No.
VR2529); (5) a virus i-VVNADL delta Dra in a culture

designated as i-VVNADL delta Dra maintained in a private
repository at the campus of the University of Nebraska, in a

repaired by replacement of a Small fragment amplified from
viral cdNA by RT-PCR. Sequence information present in all
of the plasmids representing each region of the BVDV
genome was verified and repaired.
Functional integrity of the T7 promotor, the 5'-UTR, and
the ORF of one intermediate plasmid which encompasses
the 5'-5.5 kb of the BVDV genome is verified by transfection
of linearized pBV18-F2 plasmid DNA into bovine cells
infected with a vaccinia virus producing T7 RNA poly
merase. Because the T7 promoter in pBV18-F2 directs the
Synthesis of RNA transcripts representing the region of the
BVDV genome encoding for the structural proteins of the
virus, transfected bovine cells were probed with monoclonal

65

viral genome and the functional 5’- and 3'-termini in viral
genomic RNA BVDV rescued from the infectious cl)NA
clone had an in vitro phenotype virtually identical to the WT
parent, the NADL strain of BVDV.
A genomic deletion of a Single codon in the infectious
clone, encoding glutamic acid at position 1600 of the viral
polyprotein, gave rise to Sequence tagged BVDV readily
identified by restriction fragment length polymorphism
analysis of reverse transcription-polymerase chain reaction

(RT-PCR) amplicons. Suitability of the molecular clone of
BVDV for genomic manipulations was shown by Substitu

6,001,613
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S
tion of the major envelope glycoprotein E2/gp53 with that of
the Singer Strain, giving rise to a chimeric virus. The
predicted change in antigenic Structure of the chimeric virus
was identified with strain-specific Mabs by neutralization or
immunofluorescence assay.

Embryonic bovine trachea (EBTr) cells and the NADL
strain of BVDV were obtained from the American Type

Culture Collection (CCL-44 and VR-534). This strain of
BVDV was isolated from the spleen of a naturally-occurring

fatal case of BVDV infection.

In this process, a set of five plasmids bearing overlapping
cDNAS from the BVDV genome are used to assemble a full
length copy of the viral genome in a single plasmid DNA
molecule, following Standard procedures. These five plas
mids are the five plasmids maintained in five cultures in the

15

refrigerator (Room VB5 151) in the Veterinary Basic Sci

ence Building, Department of Veterinary Science, Univer
sity of Nebraska, Lincoln, Nebr. 68583 designated as
pBV18, BV116b, pBVD79, pBVF2 and pBVSD2,3.
In FIG. 1, there is shown a flow diagram of an assembly
proceSS comprising Seventeen intermediate cloning Steps to
join the original cDNA clones, to incorporate the missing 5'and 3'-termini of the viral genome, to restore the altered
BVDV genomic Sequence, as well as to tailor Signals for
runoff RNA transcription in vitro.
As shown in FIG. 1, five plasmids pBV-18; p.3V-116P;
pBVD-79; pBV-F2; and pBVSD2-3' are converted to
pBV18-T7-C1aI, pBV116-C1aI, pBVDF2-79 and pBVSD
3'-M1 uI as shown in step 11, 13, 15 and 17 respectively.
These five intermediate plasmids are converted to the plas
mid pVVNADL.
In FIG. 2, there is shown a conversion of the pBV-18
plasmid to pBV18-T7-C1a. In this process, the plasmid 12,
pBV18, has a T7 promotor and missing nt added at 5'-end
terminus of the BVDV genome in step 12. A T7 synthetic
promotor flanked by EcoRI Avril restrictive site cohesive

BVDV RNA by RT-PCR and ligating to a SacI NdeI (partly
digested) vector to form the plasmid 42, pBV116-F2. A
plasmid 44, p3V18-F2, is formed by combining the plasmid
26, pBV18-T7-C1aI modified by removal of a DNA frag
ment extracted from EcoRV site to the RsaII site, followed

25
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40

to a fragment derived from PBV 106-F2 (plasmid 42 in FIG.
6).

In FIG. 3, there is shown a conversion of the plasmid 14,
pBV116b, to the plasmid 32, p3V116-C1 al. In this process,
plasmid 14 is modified by removal of DNA fragment
extracting from the ECORV site to the REC II site, followed
by replacement with an analogous fragment derived from
BVDV RNA by RT-PCR. The reason to replace this frag
ment from this plasmid was the presence of a deletion at
position 2702. The result of the experiment is plasmid 28,
pBV116c. The plasmid 28 has modified by the insertion of
a unique C1aI site. A Xbal-C1AI- Xbal synthetic oligo
nucleotide pair was ligated resulting in a plasmid 30,
pBV116-C1aI. The plasmid 30 is treated by complete diges
tion with SacI, partial digestion in Nde, followed by frag
ment isolation, purification, and CIAP treatment to result in
a fragment 32, a linear fragment of pBV116-C1aI.*
In FIG. 4, there is shown a conversion of the plasmid 16,
pBVD79, and the plasmid 18, pBVF2, to the plasmid
40pBVF2-D79. In this process, the plasmid 18, pBVF2 is
treated by adding the missing nt at 3'-end to make overlap
ping with pBVSD2-3' and to restore the DraIII site from the
NADL by ligating oligo EcoRV-DraIII-BamHI to result in a
plasmid 34, pbVf2-DraIII. A plasmid 36, pBVF2-D79, is
prepared by digesting a plasmid 16, pBVD79, with SmaI

by replacement with an analogons fragment derived from
BVDV RNA by RT-PCR, with the plasmid 42, pBV116-F2,

using SmaI/Bsu36I (partly digested) ligated to Bsu36I/MscI

ends is ligated (covalently bonded by DNA ligase) as shown

by a plasmid 22, pBV18-T7. A unique C1al site is added by
ligating a Synthetic oligonucleotide part at EcoRI
C1 alEcoRI to result in a plasmid 24, pBV18-T7-C1 al. This
plasmid is digested with Bsu36I and MscI to obtain a DNA
fragment, labeled 26 pBV18-T7-C1al, which will be joined

and AVr, purifying the insert fragment and with ligating
into a window created in the plasmid 34, pBVF2-DraIII, by
digesting with HindIII and blunting, then digesting with
Avril and followed by CIAP treatment. The plasmid 36 is
treated by adding a unique Sac Site. A Synthetic oligonucle
otide pair bearing a SacI site flanked by E. coli cohesive ends
was ligated to form a plasmid 38, pBVF2-D79-SacI, which
in turn is digested with Nde and SacI. Purifying and
inserting the fragment to result in a plasmid fragment 40,
pBVF2-79. The plasmid 42 pBV116-F2, shown in FIG. 6, is
prepared by combining and ligating plasmid fragment 32,
shown in FIG. 3 and FIG. 6, pBV116-C1aI, modified by
removal of a DNA fragment extracted from EcoRV site to
the RSal Site, followed by replacement with an analogons
fragment derived from BVDV RNAby RT-PCR and plasmid
40, pBVF2-D79 modified by removal of a DNA fragment
extracted from EcoRV site to the RsaII site, followed by
replacement with an analogons fragment derived from

45

50

55

60

digested vector.
In FIG. 5, there is shown the conversion of the plasmid 20,
pBVSD2-3', to the plasmid 50, pBV5D3'-MCUI. In this
process, a plasmid 46, pBVSD2.3-C1aI is prepared by
ligating a synthetic DraIII-C1aI/Xba-DraIII oligonucle
otide in plasmid 20, pBVSD2-3', at a unique DraII site. The
plasmid 46, p3VSD2-3'-C1a, has the oligonucleotide Aatl
3'-end SacII-Aat I introduced to restore the missing
sequences at the 3'-end of RIBV5V genome to form a
plasmid 48, bBVSD-3". The plasmid 48, pBVSD-3' is con
verted to a plasmid 50, pBVSD-3'-M1 uI by deleting the T7
promotor located between the C1 oI and Hsell sites. A
Synthetic oligonucleotide linker bearing on M1uI recogni
tion site sequence flanked by ClaI and Hae|I cohesive ends
was cloned at this location. The plasmid 50 p3VSD-3'-M1 uI
is converted to the plasmid 52, pBVSD-3'-M1 uI by digest
ing with DraII and C1aI, and treating with CIAP
Finally, in FIG. 6 there is shown the conversion of the
plasmid 32, pBU116-C1aI, and the plasmid 40, PBVF2
D79, to the plasmid 54, pVV-NADL, which is 14.578 bp in
length. The plasmid 54 is formed by combining the plasmid
44, pBV18-F2, with the plasmid 52, pBVSD-3'-M1uI. A
purified C1a DraIII insert from plasmid 44 was ligated into
the plasmid 52 previously digested with C1 al/DraII.
The resulting plasmid, pVVNADL, consists of the full
length cDNA of the BVDV genome flanked by an upstream
T7 promoter which directs the start of transcription at
nucleotide position 1. A SacII recognition Sequence located
at the end of the BVDV 3'-UTR allows production of
positive sense RNA molecules of 12578 nucleotides by
runoff transcription with T7 RNA polymerase. Introduction
of a Sequence tag into the BVDV genome was performed by
digesting pVVNADL with DraIII and treating linear DNA
with T4 DNA polymerase to remove the 3'-overhang. The
blunt DNA was recircularized with T4 DNA ligase and the
resulting pVVNADL Dra plasmid was sequenced to verify
the three-nucleotide deletion.

65

To substitute a region of the BVDV, NADL, genome
encoding the major envelope glycoprotein, transfer vector
pVVNADL delta SA was constructed deletion of a Sal I
Aati fragment from pVVNADL, comprising all the non

6,001,613
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Structural protein-encoding region downstream of the Sa1 I
site (nucleotides 5621 to 12542). APvulI-XcmI fragment of
pVVNADLSA including E2/gp53 was replaced using stan
dard methods with a homologous cDNA fragment derived
from the Singer strain of BVDV by RT-PCR. The resulting
pVVNADLA SA-SINgp was digested with C1aI and DraIII
to isolate a fragment representing the 5'-5184 nucleotides of
the BVDV genome to be ligated to pSDM1u-3’ digested
with C1a and DraIII to create the appropriate window. The
resulting construct was designated pVVNADLSINgp and
has Singer Strain-derived genomic Sequences from nucle
otide position 2199 to 3497 replacing the original BVDV
Strain NADL Sequences.
RNA transcripts were synthesized in vitro with T7 RNA
polymerase from a template consisting of the full-length
cDNA of the BVDV genome contained in pVVNADL

8

15

linearized with SacII and treated with T4 to remove the

3'-overhang. The RNA was transcribed with bacteriophage
T7 RNA polymerase under conditions adapted from the
methods described in F. Ausubel, R. Brent, R. Kingston, J.

Moore, J. Siedman, J. Smith & K. Struhl (1987) Current
Protocols in Molecular Biology John Wiley and Sons, New

York and E. T. Schenbom and R. C. Mierendorf, Jr., (1985)
Nucleic Acids Res 13, 6223–36.

Transcription reaction products were analysed by gel
electrophoresis and Northern analysis, using a probe derived
from the 5'-end of the BVDV genome. RNA synthesized in
vitro was digested with RNase-free DNase I, precipitated
with isopropanol, washed in ethanol and used to transfect
EBTr cells by electroporation as described below. Controls
included the electroporation of a transcription mix lacking
template DNA, or T7 RNA polymerase, or the use of a

25
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Integrity of the open reading frame (ORF) was assessed
on Bovine Testicle (BT) cells infected with vaccinia MVA
T7 by transient transfection gene expression. Cells were
fixed and probed for expression of E2/gp53 or NS23/p 125

40

with specific monoclonal antibodies (MAbs). RNA trans
fection was performed as follows:

Briefly, 3x10 EBTr cells resuspended in medium con

taining 3 ug isopropanol-precipitated RNA were electropo
rated by two consecutive discharges of 1700 V/cm and 25 uF
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in a 0.4 cm cuvette using a Gene Pulser instrument (Bio
Rad). RNA transfer efficiency was assessed by removing

coverslipS at 24 and 48 hours after plating and processing for
immunofluorescence using a MAb to BVDV. Production of
infectious progeny virus was assessed by harvesting culture
medium from transfected monolayers, filtering through 0.45

receiving pCEM4 DNA. E. coli strain GM119 proved to be
a more suitable host for pVVNADL than strain JM109
which led to frequent DNA deletions.
Runoff RNa transcripts synthesized in vitro with phage T7
RNA polymerase from SacII-linearized pVVNADL were
largely Subgenomic in size with only a minor proportion of
BVDV genome-length RNA molecules. Transfection of this
unselected heterogeneous population of transcripts into
EBTr cells by electroporation resulted in typical BVDV
cytopathology, Such as vacuolation and detachment from the
matrix, after 72 hours. In contrast, EBTr cells transfected
with truncated Subgenomic transcripts processed in the same
fashion did not show these changes. Expression of Structural
and nonstructural BVDV proteins was observed in 1-3% of
the EBTr cell population as early as 24 hours after trans
fection by immunofluorescence with BVDV-specific MAbs.
The proportion of positive cells rose to 10-20 percent by 48
hours following transfection.
Cell culture fluids were harvested periodically and used
for the propagation of the rescued infectious virus on bovine

testicle (BT) cells to carry out genetic and phenotypic
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characterization. Culture Supernatants from EBTr cells
transfected with pVVNADL-templated transcripts caused
cytopathic changes in bovine testicle BT cells 48 hours after
inoculation, while cell culture medium from control EBTr

urn membranes and inoculation onto BT cells. Infection of

BT cells was monitored by development of cytopathology
and immunostaining with Specific Mabs. Stocks of
transfection-rescued virus were prepared after three in Vitro
passages to be used to determine genotype and phenotype.
Phenotype analyses of all plasmid-derived viruses were
carried out on StockS prepared after three cell culture pas
Sages and included plaque morphology, as well as growth
kinetics analyses at three incubation temperatures, 35 C.,
37 C. and 39.5 C. by standard protocols. Antigenic analy
SeS included Seroneutralization assays and immunofluores
cence probing using a panel of 9 MAbs which recognize
E2/gp53 polymorphisms or conserved EO/gp48 apitopes.
Bovine testicle cells were infected with BVDV at an input
multiplicity of five and the monolayers lysed at 18 hours
after infection for RNA extraction. RT PCR was performed

of E. coli, strain GM119 or JM109, hosts transfected with

Supercoiled pVVNADL DNA on amplicillin-containing solid
medium is more than 100-fold lower than that of cells

truncated Subgenomic cDNA template (Sal digested). Elec

troporated cells were distributed into dishes containing glass
coverslipS to allow acetone fixation and immunostaining for
fluorescence microScopy.

with appropriate Synthetic oligodeoxynucleotide primer
pairs. DNA amplified with Taq DNA polymerase was
Sequenced.
In Summary, two plasmids were constructed, each carry
ing cDNA representing approximately the 5'- and 3'-halves
of the BVDV genome. Plasmid pBV18-F2 consists of a T7
RNa polymerase promoter abutted to the viral 5'-UTR and
adjacent polyprotein ORF Sequences encoding the viral
structural proteins. The second plasmid pBV50M1u-3'
encompasses the nonstructural protein region and the
3'-UTR of the BVDV genome followed by a SacII restric
tion endonuclease Site. These plasmids were used to join the
two halves of the viral genome to give rise to a genomic
length construct termed pVVNADL.
The integrity and continuity of the polyprotein ORF was
assessed by T7-driven transient expression of transfected
pVVNADL DNA. Cells previously infected with vaccinia
virus MVA-T7 expressing T7 RNA polymerase and trans
fected with pVVNADL DNA showed bright immunofluo
rescence following Staining with Mabs to Structural or
nonstructural viral proteins, revealing expression of genuine
BVDV proteins from an uninterrupted polyprotein ORF.
The plasmid carrying the entire genome of BVDV,
pVVNADL, contains the Co1E1 replicon derived from
pGEM4 and is 14,578 bases in length. The plating efficiency
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monolayerS transfected with truncated transcripts had no
effect. The antigenic phenotype of the virus rescued from
pVVNADL transcripts, termed i-VVNADL, was identical to
the parental NADL virus by immunofluorescence Straining
with a panel of Mabs against the E2/gp53 envelope glyco
protein and EO/gp48.
Growth parameters of the i-VVNADL at different tem
peratures were indistinguishable from parental BVDV
NADL virus by plaque morphology and kinetics of growth
determined at 35° C., 37° C., and 39.5° C. Thus, BVDV
rescued from pVVNADL is essentially identical to the
parental NADL strain of BVDV in vitro. Genetic manipu
lations of the NADL strain of BVDV involving the creation
of BVDV clNA plasmid intermediates propagated in E. coli
does not alter the in vitro phenotype of the resulting
i-VVNADL.

6,001,613
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profile identical to the Singer isolate by immunofluores

The introduction of a sequence tag into the BVDV
genome allows unambiguous identification of the viruses
rescued from plasmid-derived RNA transcripts and facili
tates the interpretation of experimental data. The model tag
should ideally be a unique Sequence, readily identifiable by
restriction fragment length polymorphism analysis and be
neutral with respect to the viral phenotype. A deletion was
introduced in the pVVNADL infectious clone which results
in loSS of a Dral restriction enzyme recognition Site and
gain of a PmlI recognition site.
An infectious virus was rescued from pVVNALDL Dra
templated transcripts with the same kinetics as with the

cence. Subtle differences were observed between these

viruses in neutralization titers with Mabs 10 and 39, but the

overall patterns remained the same.
The virus recovered from the parental pVVNADL clDNA
has a gp53 indistinguishable from that of the NADL strain.
Nucleotide sequence analyses of the i-VVNADLSINgp chi
meric virus genomic RNA across the Substituted fragment
and the flanking regions reveals the chimeric structure of the
genome. Furthermore, the 270 nucleotide bovine Sequence
insert at nucleotide 4993 characteristic of the NADL strain

intact WT cDNA infectious clone, the transfected cells

showed a large proportion of infected cells by immunofluo
rescence of coverslipS fixed at 48 hours. Characteristic
vacuolating cytopathology could be observed in transfected

15

cells between 72-96 hours after transfection and in Subse

quent passages of the culture medium onto new BT cells.
Restriction enzyme analysis of a 183 base pair amplicon
spanning the DraIII site amplified by RT-PCR from
i-VVNADL Dra revealed the presence of a PmlI site

(CACGTG) and the absence of a Dram site (CACagaGTG).

In contrast, DNA amplified from parental virus showed the
reciprocal Susceptibility to cleavage with these enzymes,
characteristic of the NADL strain of BVDV. Antigenic
analysis reveals that the i-VVNADL Dravirus is essentially
identical to the parental NADL virus as ascertained by MAb
analyses. Growth properties of i-VVNADL Dra analyzed in
vitro were similar to those of WT. Thus, the single amino
acid deleted from the vicinity of the putative cleavage Site
within p125/NS23 did not affect its viability and phenotype

25

in vitro.

Reverse genetic approaches may be used to construct
chimeras of viral genomic RNA for identification of
genomic Sequences responsible for a given phenotypic char
acter. Antigenic chimeras of BVDV prototype NADL strain
with the widely used strain Singer were constructed for this
purpose. Unique markers are present exclusively in each of
the two parental Strains and were used to identify the newly
created chimeric virus only if it carried both markers. One
marker, a unique 270 base Stretch of Sequence derived from
the cattle genome at position 4993, is characteristic of the

35

40

NADL strain of BVDV. The other marker consisted of

unique amino acid Sequences of the E2/gp53 envelope
glycoprotein which confer the Singer Strain reactivity with
Mabs 20, 31, 32, and 39 by immunoassay and neutralization.
Thus, the Singer strain does not have the 270 nucleotide
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insert while the NADL strain fails to react with the selected
set of four MAbs.

By replacing the original envelope glycoprotein in the WT
infectious clone with Sequences coding for the Singer enve
lope genes, a chimeric virus which will carry the epitopes
present in the Singer Strain envelope and the 270 nucleotide
bovine insert at position 4993 is obtained. The pVVNADL
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PvuII-XcmI fragment (position 2199 to 3497) which
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encodes for the C-terminus of E1/gp25 and the entire
ectodomain of E2/gp53 was substituted with homologous
sequences from the Singer strain of BVDV giving rise to
plasmid pVVNADLSINgp. An infectious chimeric BVOV
was recovered from transcripts derived from pVVNADLS
INgp. Plaque morphology and growth kinetics of the chi
meric virus, termed i-VVNADLSINgp, revealed that its
growth properties are virtually identical to its parental
NADL Strain virus. By contrast, the antigenic properties of
the chimeric virus depart from the BVDV strain NADL
ancestor. The pattern of reactivity of proteins encoded by
i-NADLSINgp with a panel of E2/gp53 with an antigenic

is present in i-VVNADLSINgp chimeric virus genomic
RNA, as indicated by the size of the amplicon obtained by
RT-PCR. Thus, the experimental evidence indicates that
i-VVNADLSINgp represents a chimeric virus consisting of
a genomic backbone from NADL strain of BVDV, but
expressing the Singer Strain E2/gp53 glycoprotein as well as
the C-terminal end of E1/gp25.
The simple observation that uncapped RNA transcripts
produced by T7 RNA polymerase from pVVNADL template
establishes three concepts. The first concerns the Structure of
the 5'- end of the viral RNA. RNA without a 5'-cap structure
was infectious, Suggesting that a cap-independent translation
initiation mechanism is used by BVDV genomic RNA for
gene expression. This result is compatible with biochemical
evidence Suggesting that the 5'- end of genomic RNA was
not blocked by inverted methylguanosine. The Second con
cept emerges as a corollary of the first. An internal ribosome
entry site element in the 5'-UTR of the BVDV genome
identified in reticulocyte lysates must be functional during
virus infection of cells. The third concept relates to the
sequences of the extreme 5’- and 3'-temini of the viral RNA,
thought to contain minus and plus Strand RNA replicase
promoter elements, respectively. Technical difficulties are
commonly encountered in approaches to determine the 5'and 3'-termini of large viral RNA molecules. However, the
sequences reported by Deng and Brock, “5' and 3' Untrans
lated Regions of Pestivirus Genome: Primary and Secondary
Structure Analyses,” Nucleic Acids Research, 1993, Vol 21,
No. 8, 1949–1957, and incorporated in pVVNADL gave rise
to infectious virus with WT phenotype, indicating their
functionality for the first time.
The 12,578 bases long genome of BVDV constitutes one
of the largest known positive strand viral cDNA clone which
yields infectious RNA transcripts. Moreover, the cDNA
clone is replicated as a single plasmid in E. coli. The plating
efficiency of E. coli hosts, such as strain JM109, transformed
with pVVNADL and its derivatives and plated on amplicillin
Selective medium was reduced by at least 2 orders of
magnitude as compared to the pGEM4 vector alone. In
addition, a high frequency of deletions in transformant Strain
JM109 E. coli was observed. Instability of large cDNA
clones is not uncommon and often determines utilization of

alternative Strategies involving generation of transcription
DNA templates in vitro by ligation or long PCR. However,
we found that certain strains of E. coli, notably GM119,
circumvented Such difficulties. The basis or biochemical

correlates of the greater stability of pVVNADL in this host
are unknown.
60
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Full-length runoff transcripts were produced in vitro with
low efficiencies by T7 RNA polymerase, apparently due to
the intrinsic properties of the 12.5 kB pVVNADL template.
Although the T7 RNA polymerase is highly processive for
elongation of Shorter transcripts, certain Secondary Struc
tures in nascent transcripts can act as termination Signals.
The probability of such fortuitous events increases with
transcript length. The presence of discrete Subgenomic
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length RNA molecules was sometimes observed in electro
pherograms of transcription reaction products. Low yields of
full-length transcripts are not uncommon and also occur in
other pestivirus cl)NAS as shown for hog cholera virus in
two independent reports. Unfractionated transcription prod
ucts yielded infectious viruses readily upon transfection.
Because only a relatively minor population of transcripts is
full-length, it is likely to have a high Specific infectivity.
Others have reported considerably longer delays before an
infectious virus is recovered from transfected monolayers.
The in vitro phenotype of the virus rescued from the
pVVNADL as defined by the parameters and characteristics
Studied did not depart significantly from those of the paren
tal BVDV strain NADL. Interestingly, shuttling of the large
BVDV RNA genome through cDNA in a prokaryotic plas
mid did not result in changes of the Viral phenotype in vitro.
Animal inoculation Studies will be required to determine if
the same is true of the in vitro phenotype of i-VVNADL.
The wild-type nature of the virus rescued from pVVNADL
makes it an ideal backbone to engineer changes leading to
attenuation by reverse genetic approaches.
The high plasticity that characterizes RNA genomes
makes it useful to design genomic tags that consist of more
than Single nucleotide changes to avoid reversion. However,
large insertions or deletions may result in major decreases in
replication fitness, favoring emergence of genomes repaired
by RNA recombination. A deletion of three nucleotides
(5182–5184: codon 1600) within the 270 nucleotide insert
present in the NS23 coding region of the genome was used.
Presence of this bovine sequence element at nucleotide 4993
is correlated with proteolytic processing of NS23, and the
latter coincides with Viral cytopathogenicity and virulence.
Infection of BT cells with the tagged i-VVNADL Dra

12
10f) and the presence of a unique 270 base pair bovine
sequence insert after nucleotide 4993, detected by PCR,
characteristic of the NADL parent and absent in the Singer
genome.

Neutralization of virus infectivity by Mabs results from a
high-affinity interaction between glycoprotein and antibody

(Ka values between 10 and 10' 1-mo1-'). Even minor
the affinity of the interaction (10 to 107 1.m01-') and

conformational changes in the Viral glycoprotein can lower
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(glutamic acid). Moreover, construction of chimeric virus is
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(observed), its in vitro properties are identical to the WT.
Therefore, i- VVNADL Dra constitutes a good candidate
virus with a neutral genomic tag to further examine BVDV
pathogenicity.
The glycoprotein chimera of BVDV displays a unique
antigenic phenotype without alterations in replication prop
erties in vitro. This virus can simply be traced using two
markers: the unique epitopes present in E2/gp53 of the

Singer strain of BVDV detected with specific Mabs (e.g.

also feasible, as evidence by the expression of an envelope
glycoprotein from a different BVDV strain. The two main
approaches to explore gene function in positive Strand RNA
Virus can now be implemented using infectious cDNA
clones of BVDV.

Virus resulted in cell death with the same kinetics and

features of the parental Strain. Thus, glutamic acid at posi
tion 1600 in the NADL strain polyprotein is not important
for Viral cytopathogenicity. However, this deletion resulted
in a convenient restriction fragment length polymorphism
tag providing a convenient means to discriminate between
WT and tagged genomes. Although the virulence of this
Virus in cattle has not been determined experimentally

impair neutralization without preventing binding in immu
noassays. Mabs 10 and 39 neutralized the chimeric virus to
a lesser extent as compared to the WT BVDV Singer,
Suggesting extramolecular influences on the interaction
between the Mab IgG and E2/gp53. For example, the
structure of the E2/gp53 may be affected by association with
a different E1/gp25 he tero dimer partner in
i-VVNADLSINgp leading to a decreased interaction affin
ity. Mabs 10 and 39 reacted with the chimeric virus in
immunofluorescence assays, in accordance with the well
established lower Stringency of this assay.
Reverse genetics approaches can be used to introduce
Specific alterations or tags into the BVDV genome, as
exemplified by the deletion of codon position 1600
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Although the upper size limits of viable BVDV genomes
are unknown, at least 2 KB of additional coding Sequences
can be part of viable virus. Consequently, it may be possible
to use BVDV as a vector to express foreign proteins for
immunization purposes. It will be of interest to determine if
interspecies chimeras with other pestivirus or hepatitis C and
G Virus are viable. Precedents exist in picornavirus and
flavivirus Supporting the notion that different viral functional
units can be substituted with those of distantly related virus.
Notably, the hepatitis C internal ribosome entry site element

is functional in poliovirus-hepatitis C chimeras (56). These

chimeric approaches could lead to understanding of in Vitro
host range in pestivirus and hepatitis C virus. Finally,
infectious clones could be used to engineer attenuating
mutations leading to development of novel live vaccines.
Although a preferred embodiment of the invention has
been described with Some particularity, many modifications
and variations of the preferred embodiment are possible in
the light of the above teachings. It is to be understood that,
within the Scope of the appended claims, the invention can
be practiced other than as Specifically described.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS : 1
<21 Oc
<211
<212>
<213>

<400

SEQ ID NO 1
LENGTH
TYPE

14578
DNA

ORGANISM: bovine viral diarrhea virus

SEQUENCE: 1

cacgc gitatic gatgaattcg ttaatacgac to actatagt attacga gaat tagaaaaggc

60

acticgtatac gitattgggca attaaaaata ataattaggc citagg galaca aatc.ccitcto

120

agcigaaggcc gaaaagaggc tagcc at gcc cittagtagga citagcataat gaggggggta

6,001,613
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16
-continued

accacttgga aggaatactic acctggaatg aagctggaag acacaatggit cattgcttgg

264 O

tgcgaagatg ggaagttaat gtacctocaa agatgcacga gagaalaccag atatotogca

27 OO

atcttgcata caagagccitt gcc gaccagt gtgg tattoa

tgatggg.cga.

276 O.

aa.gcaa.gagg atgtag toga aatgaacgac aactittgaat ttggacitctg cc catgtgat

282O

gccaaaccola tagtaagagg gaagttcaat acaacgctoc tgaacgg acc ggcct tccag

2880

atgg tatgcc ccataggatg gacagggact gtaagct gta cgtcattcaa tatggacacc

2.940

aaaaacticitt

ttagccacaa citgtggtacg gacatataga aggtotaaac

cattcc.ctica

tgitatcacco aaaagaatct gggggaggat

ctic catalact

gcatccttgg aggaaattgg

3060

acttgttgttgc citggagacca

alaagggggct citattgaatc ttgcaagtgg

312 O

acco cattgg caagtgtaaa

318O

ttggagaacg agacitggitta caggctagta gacagtacct cittgcaatag agalaggtgtg

324 O

actactatac

tgtggctato aatttaaaga gagtgaggga

citaccacact

taggcaaggc

gccatagitac cacaagggiac attaaagtgc aagataggaa aaacaactot acaggtoata
gctatogata ccaaactcgg accitatgcct tgcagaccat atgaaatcat atcaagtgag

3360

gggCCtgtag aaaaga cago gtgtacttitc

agacattaaa aaataagtat

342O

tittgagcc.ca gag acagota citttcagdaa tacatgctaa aaggagagta tdaatactgg

3480

tittgacctgg aggtgactga ccatcaccgg gattactitcg citgagtc.cat attagtggtg

354. O

gtag tag.ccc tottgggtgg cagatatgta citttggittac tggttacata catggtotta

3600

to agaacaga aggccittagg gattcagtat ggatcagggg aagtggtgat gatgggcaac

3660

ttgctaacco

tgctgct gta cctactgctg

372 O

agggaggaga gcqtaaagaa gtgggtotta citctitat acc acatcttagt ggtacaccca

378 O.

atcaaatctg taattgttgat cct actogatg attggggatg tggtaaaggc cgatticaggg

384 O

ggcCaagagt actitggggaa aatagaccitc tgttttacaa cagtag tact aatcgtoata

39 OO

ggitttaatca tagctagg.cg tgacccaact atagt gccac tggtaacaat aatgg cago a

396 O

citgagggtoa citgaactgac ccaccagoct ggagttgaca togctgtggc ggtoatgact

4020

tgatggittag citatgtgaca gattattitta gatataaaaa atggittacag

408 O

tgcattctda gcc togtatc tgcggtgttc ttgataagaa gcctaatata ccitaggtaga

414 O

atc.gagatgc cagaggtaac

talactittaat actattatat

4200

ttgatctoaa caacaattgt aac gaggtgg aaggttgacg tggctggcct attgttgcaa

4260

tgtgtgccita tottattgct ggtoacalacc ttgtggg.ccg

cctaatactg

4320

atcctgccta cctatogaatt ggittaaatta tactatotga aaactgttag gactgataca

4.380

gaaagaagtt ggctaggggg gatagacitat acaagagttg

cgacgttgat

4 440

ataa.cccitac

ataacaatat

tgaagtggtg

taticccaaac

alactacacta

acatactitct

tggagaccac

actitcttaac

actic catcta

gaga.gtggag agggcgtata

totttittc.ca

tdaaggcaga aag Cacaggg gaatttittct

4500

atactcittgc

agcaa.cactg ataagttgcg to agcagtaa atggcagcta

45 60

cc cittatcaa.

atatacatga gttacttaac tittgg actitt atgtactaca tgcacaggaa agittatagaa
gagatctoag gaggtaccala

catalatatoc

aggittagtgg cagdacticat agagctgaac

tggtocatgg aagaagagga gag caaaggc ttaaagaagt

4680

gtctggalagg

474. O

acatalaggta aggaatgaga cc.gtggcttic ttggtacggg

4800

gaggaggaag totacggitat gccaaagatc atgactataa tdaaggc.ca.g tacactgagt

4860

alaga gCaggC actgcataat atgcactgta tgtgagggCC gaga.gtggaa aggtogCacc

4920

tgcc caaaat gtggacgc.ca tgggalagcc.g ataacgtgtg ggatgtc.gct agcagattitt

4.980

ttgaga aacc

taataataaa.

tittatctatt

6,001,613
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26
-continued

tgcgittatcc cct gattctg toggata accg tattaccgcc tittgagtgag citgat accgc

14520

togcc.gcago C galacga.ccg agcgcagoga gtcagtgagc gaggaag.cgg aagagcgc

14578

The following is claimed:
1. A method of producing recombinantly engineered
infectious bovine Viral diarrhea virus comprising:
providing a vector comprising a reverse transcribed copy

creating a recombinantly engineered infectious bovine
viral diarrhea virus;
1O

of bovine viral diarrhea virus RNA;

recombinantly engineering the reverse transcribed copy

viral diarrhea virus.

of the bovine viral diarrhea virus;

transforming an E. coli with the vector;
causing the transformed host cell to produce a plurality of

15

Vectors,

extracting the plurality of vectors from the transformed
host cell;

forming a plurality of synthesized RNA from the plurality
of vectors comprising the reverse transcribed copy of
introducing the Synthesized RNA into a mammalian cell;
25

recovering the recombinantly engineered infectious
bovine viral diarrhea virus from the mammalian cell.
2. The method of claim 1 wherein the E. coli is strain
GM119.

3. The method of claim 1 wherein the step of introducing
the bovine viral diarrhea virus RNA into the mammalian cell

utilizes electroporation.
4. The method of claim 1 wherein the mammalian cell is

an embryonic bovine tracheal cell.
5. The method of claim 1 wherein the vector comprises
pVVNADL-SINgp.

of bovine viral diarrhea virus RNA;

recombinantly engineering the reverse transcribed copy

tors from the transformed E. coli,

forming a plurality of synthesized RNA from the plurality
of recombinantly engineered vectors comprising the
reverse transcribed copy of bovine viral diarrhea virus
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14. The vector of claim 13 wherein the vector comprises
pVVNADL-SINgp.
15. The vector of claim 13, wherein the synthesized RNA
is introduced into EBTr cells.

50

16. An isolated vector comprising sequence ID. N.O. 1.
17. A vector comprising pVVNADL-SINgp.
18. A vector comprising pVVNADLADra.
19. A chimeric virus comprising i-VVNADL-SINgp.
20. A recombinant bovine viral diarrhea virus comprising
i-VVNADLADra.
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21. A plurality of recombinantly engineered infectious
bovine viral diarrhea virus produced by the proceSS com
prising:
providing a vector comprising a reverse transcribed copy
of a genome of bovine viral diarrhea virus RNA;
creating a recombinantly engineered infectious bovine
viral diarrhea virus;

causing a host cell to produce a plurality of recombinantly
engineered infectious bovine viral diarrhea virus, and
isolating the plurality of recombinantly engineered infec

bovine viral diarrhea virus.

9. A method of isolating a plurality of recombinantly
engineered bovine viral diarrhea virus comprising:
providing a vector comprising a reverse transcribed copy
of a genome of bovine viral diarrhea virus RNA;

13. A chimeric vector comprising a 270 nucleotide insert
and an envelope glycoprotein from Singer Strain bovine viral
diarrhea virus wherein the vector is adapted to produce a
chimeric infectious bovine viral diarrhea virus.

RNA;

introducing the synthesized RNA into an embryonic
bovine tracheal cell by electroporation; and
recovering the recombinantly engineered infectious

11. An isolated vector adapted to produce recombinantly
engineered infectious bovine viral diarrhea virus.
12. The vector of claim 11, further comprising a Sequence
tag.

of the bovine viral diarrhea virus to form a recombi

nantly engineered vector;
transforming E. coli, strain GM119, with the recombi
nantly engineered vector;
causing the transformed E. coli to produce a plurality of
the recombinantly engineered vectors;
extracting the plurality of recombinantly engineered vec

causing the transformed E. coli to produce a plurality of
the recombinantly engineered pVVNADL,
extracting the plurality of recombinantly engineered
pVVNADL from the transformed E. coli,
forming a plurality of synthesized RNA from the plurality
of recombinantly engineered pVVNADL,
introducing the plurality of synthesized RNA into an
embryonic bovine tracheal cell by electroporation; and
recovering the recombinantly engineered infectious
bovine viral diarrhea virus.
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6. The method of claim 1 wherein the vector contains a
Selective marker for transformed cells.

7. The method of claim 1 wherein the vector comprises
pVVNADLADra.
8. A method of producing recombinantly engineered
infectious bovine Viral diarrhea virus comprising:
providing a vector comprising a reverse transcribed copy

10. A method of producing recombinantly engineered
infectious bovine Viral diarrhea virus comprising:
providing a pVVNADL,
recombinantly engineering pVVNADL to form a recom
binantly engineered pVVNADL,
transforming E. coli, strain GM119, with the recombi
nantly engineered pVVNADL to form a transformed E.
coli,

the bovine viral diarrhea virus RNA;
and

causing a host cell to produce a plurality of recombinantly
engineered infectious bovine viral diarrhea virus, and
isolating the plurality of recombinantly engineered bovine
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tious bovine viral diarrhea virus.

